Acute Myeloid Leukemia , 1st ed. 2021 Hematologic Malignancies Series

Langue : Anglais

Couverture de l’ouvrage Acute Myeloid Leukemia

Résumé
Sommaire
Biographie
Commentaire

This book, written by a team of leading experts, provides a comprehensive overview of acute myeloid leukemia (AML), the most frequent acute leukemia in adults. The opening chapters present current knowledge of epidemiology, etiologic factors, and the pathogenesis and molecular development of AML. Detailed guidance is offered on laboratory and clinical diagnostic workup and disease classification, and the patient- and disease-related factors that determine prognosis and treatment allocation are identified. On the basis of these general considerations, initial treatments in patients considered fit for intensive treatment and in older and co-morbid patients are reviewed, and the available relapse treatment strategies, explained. For all clinical scenarios, the most recent data on the optimal use of newly approved agents in different AML subgroups are presented. Separate chapters address the treatment of acute promyelocytic leukemia, current practice of allogeneic stem cell transplantation, and special clinical situations. Finally, promising approaches in drug development, current standards and challenges in assessment of measurable residual disease, immune approaches, and ideas for innovative trial designs are considered.

1. Epidemiology and Etiology.- 2. Diagnosis and Classification of AML: WHO 2016.- 3. The Genomic Landscape and Clonal Evolution of AML.- 4. Clinical Manifestation and Diagnostic Workup.- 5. Prognostic Factors and Treatment Allocation.- 6. Treatment of Acute Promyelocytic Leukemia.- 7. Treatment of Newly Diagnosed AML in FitPatients.- 8. Treatment of Newly Diagnosed AML in Unfit Patients.-

9. Treatment of Relapsed and Refractory AML.- 10. Allogeneic Stem Cell Transplantation.- 11. Special Clinical Scenarios.- 12. Future Developments.

Christoph Röllig, MD, is Professor of Medicine at the University of Dresden, Germany. Dr. Röllig received his medical training at the Free and Humboldt Universities of Berlin, Germany, and graduated in 1998. From 1999 to 2006, he undertook an internship in internal medicine and hematology and oncology at the University Hospital in Dresden, becoming a certified specialist for internal medicine in 2005 and for hematology and medical oncology in 2006. From 2006 to 2007, he did a Master’s degree in Public Health and Health Services Research at the London School of Hygiene and Tropical Medicine. He then worked in evidence-based medicine and guideline development at the Agency for Quality in Medicine in Berlin, Germany. Since 2009, Dr. Röllig has been a consultant hematologist and head of the hematological Clinical Trial Unit at the University Hospital in Dresden and has also led the central study office of the Study Alliance Leukemia (SAL) as SAL secretary. He acts as a reviewer for several hematological journals (New England Journal of Medicine, Blood, Lancet Oncology, Leukemia, Cancer, Bone Marrow Transplantation, Haematologica) and for the annual meetings of the European Haematology Association and American Society of Hematology. His main research interest are treatment optimization and real-world data in AML. He has acted as coordinating investigator in several phase II and III trials evaluating treatment optimization in AML and is the first and coordinating author of the AML guidelines of the German, Austrian and Swiss hematologic societies. He is a member of Working Group for Clinical Trials at the German Society for Hematology and Oncology (DGHO) and member of the Scientific Working Group for AML at the European Haematology Association (EHA).

Gert Ossenkoppele was appointed as Professor of Hematology at the VU University Medical Center in Amsterdam, NL, in 2003. He obtained his doctorate in medicine at that same University in 197

Explanation of diagnostic workup and disease classification

Clear guidance on initial treatment and relapse strategies

Information on optimal use of newly approved agents